Oligonucleotide analog and method for treating flavivirus infections
CA 2533218 C · Owner: Avi Biopharma, Inc. · Inventors: Iversen, Patrick L.; Stein, David A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method of inhibiting replication of a flavivirus in animal cells and an , oligonucleotide compound for use in the method are disclosed. The oligonucleotide analog (i) has a nuclease-resistant backbone (ii) is capable , of uptake by the cells (iii) contains between 8-40 nucleotide bases and (iv) , has a sequence of at least 8 bases complementary to a region of the virus' positive strand RNA genome that includes at least a portion of SEQ ID NOS: 1- 4. Exposure of cells infected with a flavivirus to the analog is effective to form within the cells, a heteroduplex structure composed of the virus ssRNA and the oligonucleotide, characterized by a Tm of dissociation of at least 45 ~C. and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 5, 2004 and granted November 18, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 5, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 5, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.